Treats symptomatic benign prostatic hyperplasia (BPH). Sold as Jalyn. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 16, 2026, FDA lists 5 applications for Dutasteride; Tamsulosin Hydrochloride (sold as Jalyn), first approved Jun 14, 2010, with 0 new uses approved and 0 published complete response letters.
| Dutasteride-Tamsulosin | Part D | $8.5M | -10% | 12,586 |
| Jalyn | Part D | $0K | -100% | 0 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male SubjectsBenign Prostatic Hyperplasia · Addpharma Inc. | Phase 1 | Recruiting | Mar 2, 2026 |
| Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic HyperplasiaProstatic Hyperplasia, Benign, Erectile Dysfunction · EMS | Phase 3 | Not yet recruiting | Feb 20, 2024 |
| Prostate Medication, Metabolism and Gut MicrobiotaProstatic Hyperplasia, Prostate Cancer · Turku University Hospital | Phase 4 | Recruiting | Aug 21, 2023 |
| Jun 14, 2010 | JalynNDA 22460 · New combination | Waylis Therap | 9 | Marketed |
| Feb 26, 2014 | Dutasteride And Tamsulosin HydrochlorideANDA 202509 | Ph Health | 2 | Discontinued |
| Nov 20, 2015 | Dutasteride And Tamsulosin HydrochlorideANDA 202975 | Actavis Labs Fl Inc | 0 | Discontinued |
| May 24, 2018 | Dutasteride And Tamsulosin HydrochlorideANDA 207769 | Zydus Pharms | 1 | Marketed |
| Jul 18, 2024 | Dutasteride And Tamsulosin HydrochlorideANDA 213300 | Aurobindo Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA